Your institution may have access to this item. Find your institution then sign in to continue.
Title
Lynparza Now Approved as Maintenance Therapy for BRCA-Mutated Metastatic Pancreatic Cancer.
Abstract
The article discusses approval of lynparza by food and drug administration as maintenance therapy for BRCA-mutated metastatic pancreatic cancer. It mentions that the approval was based on results of the POLO study, a double-blind, multicenter, phase 3 clinical trial of patients with deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic cancer.